ClinicalTrials.gg

Program

ER2001

A development code. Also written as “ER2001 injection” and “ER2001 intravenous injection”.

Its studies are mostly in Huntington Disease, led by ExoRNA Bioscience.

Furthest: phase 2, since Jan 5, 20263 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ExoRNA Bioscience31 open or runningphase 2since Jan 5, 2026May 25, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 25, 2023First study: early phase 1 study in Huntington DiseaseFirst studyNCT06024265 · 10 enrolled · China
  2. Jan 5, 2026Phase 2 study in Huntington DiseasePhase 2 reachedNCT07339514 · 27 enrolled · China
  3. Jan 7, 2026Early phase 1 study in Huntington DiseaseNCT07344519 · 8 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07344519Huntington Disease · ChinaEarly 1CompletedJun 1, 20258
NCT07339514Huntington Disease · China2Active, not recruitingApr 1, 202627
NCT06024265Huntington Disease · ChinaEarly 1CompletedJan 31, 202510

How it is read

Names in the registry

  • “ER2001 injection”, 2 entries
  • “ER2001 intravenous injection”, 1 entry

Codes read as this program: ER2001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.